Effectiveness of cold cap in the prevention of docetaxel-induced alopecia
Effectiveness of cold cap in the prevention of docetaxel-induced alopecia
复制标题
DOI：
10.1016/s0959-8049(96)00374-7
复制
发表时间：
1997-02-01
影响因子：
8.4
通讯作者：
Bonneterre, J
中科院分区：
文献类型：
--
作者：
Lemenager, M;Lecomte, S;Bonneterre, J
多西他赛是一种新型紫杉醇类化疗药物，对乳腺癌有较好的临床疗效。多西他赛引起的最令人痛苦的副作用之一是脱发。我们研究了98例接受100 mg/m2多西他赛每3周1小时静脉输注的患者使用冷帽预防脱发。1例患者失访。83名患者（86%）被评估为冷帽成功，因为他们表现出WHO等级脱发小于或等于2，并且不需要戴假发。14例患者（14%）必须戴假发;其中7例患者在3个周期的评价前退出。冷帽是一种非常有效的技术，对紫杉醇治疗的患者具有最小的副作用。(C)1997 Elsevier Science Ltd.
Docetaxel is a new taxoid antineoplastic agent with clinical efficacy especially in breast cancer. One of the most distressing side-effects induced by docetaxel is alopecia. We studied the prevention of alopecia by using a cold cap in 98 patients receiving 100 mg/m(2) docetaxel by 1 h i.v. infusion every 3 weeks. One patient was lost to follow-up. 83 patients (86%) were evaluated as a success to the cold cap, as they presented WHO grade alopecia less than or equal to 2 and no need to wear a wig. 14 patients (14%) had to wear a wig; among them, 7 patients withdrew before the evaluation at three cycles. The cold cap is a very effective technique with minimal side-effects for docetaxel-treated patients. (C) 1997 Elsevier Science Ltd.